{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CDDP+75&page=2", "query": { "intervention": "CDDP 75", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CDDP+75&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-13T07:37:49.792Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03012477", "title": "CISPLATIN + AZD-1775 In Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple-negative Metastatic Breast Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2017-01-18", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2021-11-23", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012477" }, { "nct_id": "NCT03631784", "title": "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab 200 mg", "type": "DRUG" }, { "name": "Paclitaxel 45 mg/m^2", "type": "DRUG" }, { "name": "Carboplatin AUC6", "type": "DRUG" }, { "name": "Cisplatin 75 mg/m^2", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m^2", "type": "DRUG" }, { "name": "Thoracic Radiation Therapy (TRT)", "type": "RADIATION" }, { "name": "Paclitaxel 200 mg/m^2", "type": "DRUG" }, { "name": "Carboplatin AUC2", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2018-10-19", "completion_date": "2024-03-19", "has_results": true, "last_update_posted_date": "2025-03-25", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 10, "location_summary": "Santa Rosa, California • Evanston, Illinois • Fort Wayne, Indiana + 7 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631784" }, { "nct_id": "NCT05722015", "title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab Formulated with Berahyaluronidase Alfa", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Pegylated filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 377, "start_date": "2023-02-14", "completion_date": "2028-05-22", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Clermont", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722015" }, { "nct_id": "NCT01232452", "title": "A Study in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cixutumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2011-04", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 5, "location_summary": "Chicago, Illinois • Hackensack, New Jersey • Portland, Oregon + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232452" }, { "nct_id": "NCT05261399", "title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma", "Non-Small-Cell Lung" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 341, "start_date": "2022-08-03", "completion_date": "2026-11-23", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 5, "location_summary": "Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05261399" }, { "nct_id": "NCT01221753", "title": "Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck", "Human Papilloma Virus" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2011-07", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221753" }, { "nct_id": "NCT04711824", "title": "Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Brain Metastases, Adult" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Physicians Choice systemic chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Colette Shen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2022-03-09", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711824" }, { "nct_id": "NCT01285557", "title": "Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction" ], "interventions": [ { "name": "S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)", "type": "DRUG" }, { "name": "Fluorouracil/cisplatin (control arm)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2011-04-14", "completion_date": "2014-08-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 4, "location_summary": "Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more", "locations": [ { "city": "Alexandria", "state": "Louisiana" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285557" }, { "nct_id": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab 200 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab 400 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab placebo (saline)", "type": "DRUG" }, { "name": "Olaparib 300 mg BID", "type": "DRUG" }, { "name": "Olaparib matching placebo", "type": "DRUG" }, { "name": "Etoposide 100 mg/m^2", "type": "DRUG" }, { "name": "Platinum, investigator's choice", "type": "DRUG" }, { "name": "Standard Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Prophylactic Cranial Irradiation (PCI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 672, "start_date": "2020-12-08", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 35, "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624204" }, { "nct_id": "NCT00391586", "title": "Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Platinum-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 45, "start_date": "2006-07", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2015-08-17", "last_synced_at": "2026-09-13T07:37:49.792Z", "location_count": 5, "location_summary": "Albuquerque, New Mexico • Santa Fe, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Santa Fe", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00391586" } ] }